4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine → 4-(2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine

HRID 1923156

反応式

HRID 1923156 の反応式
[C:1]([N:5]1[CH2:10][CH2:9][N:8]([CH2:11][C:12]2[N:13]([CH3:28])[C:14]3[C:19]([N:20]=2)=[C:18]([N:21]2[CH2:26][CH2:25][O:24][CH2:23][CH2:22]2)[N:17]=[C:16](Cl)[N:15]=3)[CH2:7][CH2:6]1)([CH3:4])([CH3:3])[CH3:2].[N:29]1([C:33]2[NH:37][C:36]3[CH:38]=[CH:39][CH:40]=[CH:41][C:35]=3[N:34]=2)[CH2:32][CH2:31][CH2:30]1>>[N:29]1([C:33]2[N:34]([C:16]3[N:15]=[C:14]4[C:19]([N:20]=[C:12]([CH2:11][N:8]5[CH2:9][CH2:10][N:5]([C:1]([CH3:2])([CH3:3])[CH3:4])[CH2:6][CH2:7]5)[N:13]4[CH3:28])=[C:18]([N:21]4[CH2:26][CH2:25][O:24][CH2:23][CH2:22]4)[N:17]=3)[C:35]3[CH:41]=[CH:40][CH:39]=[CH:38][C:36]=3[N:37]=2)[CH2:32][CH2:31][CH2:30]1

参加物

3

反応物 2

HCID 596054704-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholineHCID 596058832-(azetidin-1-yl)-1H-benzo[d]imidazole

生成物 1

HCID 596054164-(2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine

実験手順

4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (75 mg) was reacted with 2-(azetidin-1-yl)-1H-benzo[d]imidazole (33 mg) via General Procedure for Buchwald coupling to give 36.1 mg 454 following reverse phase purification. MS (Q1) 545.4 (M)+

後処理

  1. customto give
  2. custom36.1 mg 454 following reverse phase purification

出典と根拠

ORDレコード
ord-bc5990d9206546588080d79b4df42b98
出典データセット
uspto-grants-2012_05
特許番号
US08173650B2

関連ノート

読み込み中…